



In situ Immunotherapy Platform

Despite great progress made with immune check point inhibitors, 2 major challenges remain:


- Efficacy (20-40% of responders)
- Safety (60-90% of adverse events)

**INSTITUT
pasteur**

Measovir® platform

- Based on measles virus vaccine (MV)
- Designed by Pr Tangy, cofounder and CSO
- 2024-2028 LabCom with Institut Pasteur

ONCOVITA



VACCINES

against infectious diseases

12 candidates; 4 in clinical trials:
Chikungunya, Zika, Lassa, Covid-19

Licensed to



Acquired by




IMMUNO-VIROTHERAPY

against cancer


A candidate: MVdeltaC
Several 2nd generation products

Why Measles is the right virotherapy backbone

The live attenuated measles vaccine has safely reached more than 4 billion people and has demonstrated strong safety in oncology trials across more than 200 patients.




Measles naturally infects CD46 overexpressing tumor cells, providing a built in selectivity advantage across mesothelioma, TNBC and additional solid tumors.



MVdeltaC harnesses a well understood and effective immune response to target hard-to-treat solid tumors



Its ability to stimulate strong innate and adaptive immunity makes it a robust platform for revealing tumors and initiating systemic immune responses.



Measles replicates only in the cytoplasm and does not interact with host DNA, reducing long term risks associated with other viral backbones.



The evidence Clinical and preclinical

A documented remission in a patient with triple negative breast cancer highlights MV based immunotherapy potential to infect and clear aggressive tumors that resist standard immunotherapy.


A Croatian virologist cured her breast cancer by self-administering an experimental treatment

By Elisa Doré, Le Figaro Santé



Beata Halassy chose to use two viral strains, including the classic measles vaccine to treat her breast cancer.


MVdeltaC produces complete tumor regressions and long-term survival across mesothelioma, TNBC, and other aggressive tumor preclinical models.



Strong abscopal control in contralateral tumor models demonstrates the systemic immunity and memory triggered by MVdeltaC.


Combination studies show one hundred percent survival with anti CTLA4, supporting a clear expansion path into combination immunotherapy strategies.

1 Strong in vitro oncolytic activity in tumor cell lines




- Oncolytic activity of MVdeltaC was evaluated in vitro on 127 human cell lines representing 8 different type of cancer.
- Enhanced and faster oncolytic activity compared to the standard vaccine virus (MV)
- Over 70% of cancers tested responded to treatment. No effect on healthy non cancer cells.

2 Antitumor in vivo activity in PDX models immunodeficient mice by intratumoral administration




- Inhibition of tumor growth (low dose)
- Complete tumor lysis (high dose)

3 Antitumor activity in immunocompetent syngeneic A/J mice grafted mouse NS20Y neuroblastoma by IT administration




- Tumor growth was inhibited after only 3 IT injections, with a complete response in 72% of MVdeltaC-treated animals and high survival rate.
- A rechallenge performed 64 days later showed no tumor growth demonstrating the establishment of a long-lasting immune memory.

4 Massive infiltration of CD4+ and CD8+ T lymphocytes in MVdeltaC treated tumors



- Recruitment of CD8+ and natural killer lymphocytes demonstrate the role of innate and adaptive immune system in MVdeltaC tumor rejection.

Opportunity to Advance Cancer Therapy



Market Opportunity


- ~8.900 eligible patients per year in EU, US and in Japan
- Estimated peak sales / €600M on initial indications
- ODD for MVdeltaC in PM granted by FDA on going in the EU

Future Growth Drivers

- Can address all solid tumor market ie €500 billion
- Potential for combination with ICI

This stepwise strategy builds early proof in an orphan indication and then extends MVdeltaC into larger solid tumor markets where revealing hidden tumors is a transformative advantage.

Development plan and Milestones



Team and Advisory Board

Management Team



Jean-François Le Bigot, PhD
Executive Chairman



Stéphane Altaba, PhD, ESCP
CEO




Frédéric Tangy, PhD
CSO & Founder



Stéphane Champiat, MD, PhD
Medical Advisor



Patrick Spies
CFO



Véronique Riebbels, PhD
Program Manager

KOLs Consulted



Stéphane Champiat, MD, PhD
Associate Professor at MD Anderson Cancer Center, US



Pr. Aurelien Marabelle, MD, PhD
Professor of Clinical Immunology, Paris-Saclay University



Pr. Eric Deutsch, MD, PhD
Chairman of Radiation Oncology at Gustave Roussy



Barbara Pistilli, MD
Head of the Breast Cancer Unit at Gustave Roussy



Jean Francois Fonteneau, PhD
Cancer Immunotherapy & Oncolytic Virotherapy, Nantes University



Pr. Arnaud Scherpereel, MD, PhD
Pulmonary and Thoracic Oncology Department, Lille University Hospital

Executive Summary

Company: PreIND/ development stage company ready to enter into clinic.

Focus: Oncology

Technology: Measovir® platform – a proprietary therapeutic vaccine technology based on genetically modified Measles vaccine vector

Lead Candidate – MVdeltaC

- Pre-IND/CTA stage
- Strong preclinical efficacy data
- Outstanding safety track record (based on >4 billion vaccine doses)
- GMP batch production in progress
- >20 Peer-reviewed publications on oncolytic measles
- Orphan Drug Designation (ODD) granted by FDA for Pleural Mesothelioma (PM) and on going application in EU
- Two positive scientific advice meetings with French regulatory authorities
- Robust IP position and full freedom to operate
- Other Measovir® constructed candidates under preclinical testing

Funding Sought/ use of proceeds

- €10M : 2026 to 2028 for Phase I a first-in-human (FIH) study in monotherapy and in combination with an ICI
- €10M : 2028 to 2029 for Phase IIa study in PM and Triple-Negative Breast Cancer (TNBC)

Contact Information :

Stéphane Altaba, PhD, ESCP

CEO

Phone: +33 (0)6 72 87 20 03

Email: stephane.altaba@oncovita.fr

Patrick Spies

CFO

Phone: +33 (0)6 19 39 31 91

Email: patrick.spies@oncovita.fr